NL-OMON45576已完成不适用
Safety and protective efficacy of genetically modified Plasmodium berghei (Pb(PfCS@UIS4)) malaria parasites in healthy volunteers - PbVac
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •1. Subject is aged * 18 and * 35 years and in good health. ;2. Subject has adequate understanding of the procedures of the study and is able and willing (in the investigator*s opinion) to comply with all study requirements.;3. Subject is willing to complete an informed consent questionnaire and is able to answer all questions correctly.;4. Subject is able to communicate well with the investigator and is available to attend all study visits, lives in Rotterdam or in proximity to the trial centre (can be on site within 1 hour) or is willing to stay in a hotel close to the trial centre during part of the study (phase 1: from day of immunization to day 12 post-immunization; phase 2: from day of immunization to day 8 post-immunization. ;5. The subject will remain within the Netherlands from day -1 until day +28 after immunization during phase 1; from day -1 until day 12 after each immunization during phase 2, and during the challenge period, will not travel to a malaria-endemic area during the study period, and is reachable (24/7) by mobile telephone throughout the entire study period. ;6. Subject agrees to their general practitioner being informed and contacted about their participation in the study and agrees to sign a form to request the release by their General Practitioner (GP), and medical specialist when necessary, to the investigator(s), of any relevant medical information concerning possible contra-indications for participation in the study. ;7. The subject agrees to refrain from blood donation to Sanquin or for other purposes throughout the study period and for a defined period thereafter according to current Sanquin guidelines (3 years minimum, depending on serology).;8. For female subjects: subject agrees to use continuous adequate contraception** and not to breastfeed for the duration of study. ;9. Subject agrees to refrain from intensive physical exercise (disproportionate to the subject*s usual daily activity or exercise routine) during the malaria challenge period. ;10. Subject agrees to avoid additional triggers that may cause elevations in liver enzymes including alcohol from baseline up to 1 week post treatment.;11. Subject has signed written informed consent to participate in the trial.
排除标准
- •1. Any history, or evidence at screening, of clinically significant symptoms, physical signs or abnormal laboratory values suggestive of systemic conditions, such as cardiovascular, pulmonary, renal, hepatic, neurological, dermatological, endocrine, malignant, haematological, infectious, immunodeficient, psychiatric and other disorders, which could compromise the health of the volunteer during the study or interfere with the interpretation of the study results. These include, but are not limited to, any of the following. ;1.1. Body weight <50 kg or Body Mass Index (BMI) <18 or >30 kg/m2 at screening. ;1.2. A heightened risk of cardiovascular disease, as determined by: an estimated ten year risk of fatal cardiovascular disease of *5% at screening, as determined by the Systematic Coronary Risk Evaluation (SCORE); history, or evidence at screening, of clinically significant arrhythmia*s, prolonged QT-interval or other clinically relevant ECG abnormalities; or a positive family history of cardiac events in 1st or 2nd degree relatives <50 years old. ;1.3. A medical history of functional asplenia, sickle cell trait/disease, thalassaemia trait/disease or G6PD-deficiency. ;1.4. History of epilepsy in the period of five years prior to study onset, even if no longer on medication. ;1.5. Screening tests positive for Human Immunodeficiency Virus (HIV), active Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) ;1.6. Chronic use of i) immunosuppressive drugs, ii) antibiotics, iii) or other immune modifying drugs within three months prior to study onset (inhaled and topical corticosteroids and oral anti-histamines exempted) or expected use of such during the study period. ;1.7. Any recent or current systemic therapy with an antibiotic or drug with potential anti-malarial activity (chloroquine, atovaquone-proguanil, arthemether-lumefantrine, sulfadoxine-pyrimethamine, doxycycline, tetracycline, piperaquine, benzodiazepine, flunarizine, fluoxetine, tetracycline, azithromycin, clindamycin, erythromycin, hydroxychloroquine, etc.) (allowable timeframe for use at the Investigator*s discretion).;1.8. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years. ;1.9. Any history of treatment for severe psychiatric disease by a psychiatrist in the past year. ;1.10. History of drug or alcohol abuse interfering with normal social function in the period of one year prior to study onset, positive urine toxicology test for cocaine or amphetamines at screening or at inclusion, or positive urine toxicology test for cannabis at inclusion. ;2. For female subjects: positive urine pregnancy test at screening and/or at the baseline visits, including baseline of immunizations (I-1) and or baseline before CHMI (C-1).;3. Any history of malaria, positive serology for P. falciparum, or previous participation in any malaria (vaccine) study. ;4. Known hypersensitivity to or contra-indications (including co-medication) for use of sulfadoxine-pyrimethamine, piperaquine, chloroquine, Malarone®, artemether-lumefantrine, primaquine or history of severe (allergic) reactions to mosquito bites.;5. Receipt of any vaccinations in the 3 months prior to the start of the study or plans to receive any other vaccinations during the study period or up to 8 weeks thereafter.;6. Participation in any other clinical study in the 30 days prior to the start of the study or during the study period. ;7. Be
研究者
相似试验
已完成
不适用
Safety and protective efficacy of genetically attenuated Pf*b9*slarp (PfSPZ-GA1) malaria parasites in healthy volunteersPlasmodium falciparum10037072MalariaNL-OMON46209Sanaria67
已完成
不适用
Safety and preliminary protective efficacy of genetically attenuated Pf*mei2 (GA2) malaria parasites in healthy Dutch volunteersparasitaire ziekte10037072MalariaNL-OMON51062eids Universitair Medisch Centrum51
已完成
不适用
Evaluation of the safety and efficacy of transgenic rice containing peptides from Japanese cedar pollen allergens.Adult patient with Japanese cedar pollinosis.JPRN-UMIN000011086The Jikei University, School of Medicine43
已完成
1 期
Genetically Attenuated Malaria Parasite as potential vaccine candidate against malaria infectionmalariaACTRN12617000824369QIMR Berghofer Medical Research Institute6
已完成
3 期
?Determining efficacy and safety of recombinant growth hormone Somatin® (AryaTinaGene) compared to Norditropin® (Novonordisk) in children with growth hormone deficiencyIRCT20171122037571N1Arya Tina Gene company80